Literature DB >> 11745925

Intracellular and cell-free (infectious) HIV-1 in rectal mucosa.

M Di Stefano1, A Favia, L Monno, P Lopalco, O Caputi, A C Scardigno, G Pastore, J R Fiore, G Angarano.   

Abstract

The intestinal mucosa contains most of the total lymphocyte pool and plays an important role in viral transmission, but only slight attention has been given to the immunological and virological aspects of human immunodeficiency virus-1 (HIV-1) infection at this site. In this study, before initiating or changing antiretroviral therapy, paired blood samples and rectal biopsies (RB) were obtained from 26 consecutive HIV-infected subjects. HIV-1 isolation and biological characterization, DNA, and HIV-1 RNA titration were assessed, as were in vitro tumor necrosis factor-alpha (TNF-alpha) and interleukin-beta (IL-1beta) spontaneous production. The rate of HIV-1 isolation from peripheral blood mononuclear cells (PBMCs) and RBs was 75% and 58%, respectively. All RB-derived isolates were nonsyncytium inducing (NSI), independent of the phenotype of blood-derived isolates. Proviral DNA and detectable HIV-1 RNA levels were measured in 100% and 77% of RBs, respectively. A statistical correlation was observed between HIV-1 DNA and HIV-1 RNA levels in rectal mucosa (P = 0.0075), whereas no correlation was found between these levels in blood samples (P > 0.05). Antiretroviral treatment did not seem to influence HIV-1 detection in RBs. Higher levels of in vitro proinflammmatory cytokine production were found in the RBs of most infected patients when compared with healthy controls. Therefore, the rectal mucosa is an important HIV-1 reservoir that demonstrates a discordant viral evolution with respect to blood. Both the virus type and the mucosa pathway of immunoactive substances might have important implications for therapeutic decision-making and monitoring and could influence the bidirectional transmission of HIV-1 in mucosal surfaces. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745925     DOI: 10.1002/jmv.2084

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

Review 1.  HIV1 and the gut in the era of highly active antiretroviral therapy.

Authors:  Esteban C Nannini; Pablo C Okhuysen
Journal:  Curr Gastroenterol Rep       Date:  2002-10

2.  Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection.

Authors:  Brenna E Kiniry; Peter W Hunt; Frederick M Hecht; Ma Somsouk; Steven G Deeks; Barbara L Shacklett
Journal:  J Immunol       Date:  2018-01-19       Impact factor: 5.422

3.  Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Sara Gianella; Elizabeth Sinclair; Lorrie Epling; Qingsheng Li; Lijie Duan; Alex L M Choi; Valerie Girling; Terence Ho; Peilin Li; Katsuya Fujimoto; Harry Lampiris; C Bradley Hare; Mark Pandori; Ashley T Haase; Huldrych F Günthard; Marek Fischer; Amandeep K Shergill; Kenneth McQuaid; Diane V Havlir; Joseph K Wong
Journal:  J Infect Dis       Date:  2010-10-12       Impact factor: 5.226

4.  Characterization of cells expressing lymphatic marker LYVE-1 in macaque large intestine during simian immunodeficiency virus infection identifies a large population of nonvascular LYVE-1(+)/DC-SIGN(+) cells.

Authors:  Yang-Kyu Choi; Beth A Fallert Junecko; Cynthia R Klamar; Todd A Reinhart
Journal:  Lymphat Res Biol       Date:  2013-03       Impact factor: 2.589

Review 5.  Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure.

Authors:  Shahzada Khan; Sushama Telwatte; Martin Trapecar; Steven Yukl; Shomyseh Sanjabi
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11       Impact factor: 2.205

Review 6.  Does ART prevent HIV transmission among MSM?

Authors:  Kathryn E Muessig; M Kumi Smith; Kimberly A Powers; Ying-Ru Lo; David N Burns; Andrew E Grulich; Andrew N Phillips; Myron S Cohen
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

7.  Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs.

Authors:  Eva Malatinkova; Ward De Spiegelaere; Pawel Bonczkowski; Maja Kiselinova; Karen Vervisch; Wim Trypsteen; Margaret Johnson; Chris Verhofstede; Danny de Looze; Charles Murray; Sabine Kinloch-de Loes; Linos Vandekerckhove
Journal:  Elife       Date:  2015-10-06       Impact factor: 8.140

8.  The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time.

Authors:  Lina Josefsson; Susanne von Stockenstrom; Nuno R Faria; Elizabeth Sinclair; Peter Bacchetti; Maudi Killian; Lorrie Epling; Alice Tan; Terence Ho; Philippe Lemey; Wei Shao; Peter W Hunt; Ma Somsouk; Will Wylie; Daniel C Douek; Lisa Loeb; Jeff Custer; Rebecca Hoh; Lauren Poole; Steven G Deeks; Frederick Hecht; Sarah Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

9.  Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents.

Authors:  Sushama Telwatte; Peggy Kim; Tsui-Hua Chen; Jeffrey M Milush; Ma Somsouk; Steven G Deeks; Peter W Hunt; Joseph K Wong; Steven A Yukl
Journal:  AIDS       Date:  2020-11-15       Impact factor: 4.632

10.  Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients.

Authors:  Anne-Emmanuelle Depincé-Berger; Delphine Vergnon-Miszczycha; Alexandre Girard; Anne Frésard; Elisabeth Botelho-Nevers; Claude Lambert; Emilie Del Tedesco; Christian Genin; Bruno Pozzetto; Frédéric Lucht; Xavier Roblin; Thomas Bourlet; Stéphane Paul
Journal:  Retrovirology       Date:  2016-06-30       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.